Eligo Bioscience’s EB300 Gains Orphan Drug and Rare Pediatric Disease Designations
The FDA has granted Eligo Bioscience Orphan Drug and Rare Pediatric Disease designations for its investigational gene therapy EB003 for treating patients with Shiga-toxin producing bacterial infection to prevent hemolytic uremic syndrome (HUS), which affects the kidneys and blood vessels.
EB003 is a CRISPR-based therapy designed to target Shiga toxin-producing E. coli (STEC) bacteria in the gut of infected patients.
Preclinical data support EB003’s capacity to eliminate Shiga-toxin genes from patients’ gut, leading to a rapid decrease in toxin levels and associated symptoms and preventing their evolution towards hemolytic uremic syndrome, the company said.
There are currently no approved therapies for the potentially fatal syndrome.
About Eligo
Eligo Bioscience is a biotechology company that develops a new class of biotherapeutics for microbiome precision-editing. Eligo Bioscience is the world leader in microbiome gene editing therapy and is advancing a highly differentiated pipeline of precision medicines to address unmet medical needs in immuno-inflammation and oncology caused by the expression of specific deleterious bacterial genes by our microbiome.
Eligo was founded by scientists from The Rockefeller University and by scientists from MIT. Eligo was named a Technology Pioneer by the World Economic Forum and received venture capital funding from Khosla Ventures and Seventure Partners, and non-dilutive funding from GlaxoSmithKline, the European Commission, CARB-X, and Bpifrance.
The FDA has granted Eligo Bioscience Orphan Drug and Rare Pediatric Disease designations for its investigational gene therapy EB003 for treating patients with Shiga-toxin producing bacterial infection to prevent hemolytic uremic syndrome (HUS), which affects the kidneys and blood vessels.
About Eligo
Eligo Bioscience is a biotechology company that develops a new class of biotherapeutics for microbiome precision-editing. Eligo Bioscience is the world leader in microbiome gene editing therapy and is advancing a highly differentiated pipeline of precision medicines to address unmet medical needs in immuno-inflammation and oncology caused by the expression of specific deleterious bacterial genes by our microbiome.
Eligo was founded by scientists from The Rockefeller University and by scientists from MIT. Eligo was named a Technology Pioneer by the World Economic Forum and received venture capital funding from Khosla Ventures and Seventure Partners, and non-dilutive funding from GlaxoSmithKline, the European Commission, CARB-X, and Bpifrance.
October 12, 2022
